These immunomodulatory properties have been supported by clinical studies in populations with chronic inflammatory conditions such as type 2 diabetes and polycystic ovary syndrome, with reductions in markers like C-reactive protein (CRP) (Haffner et al., 2005; Lund et al., 2008; Tsilchorozidou et al., 2009; Diamanti-Kandarakis et al., 2006). This evidence concerns the gene CRP and polycystic ovary syndrome.